Epstein-Barr Virus and Associated Diseases

1. Front Matter

   Pages i-xv

   PDF

2. Immunodeficiency Diseases

   1. Front Matter

      Pages 1-1

      PDF

   2. Association of Epstein-Barr Virus and Lymphoproliferative Diseases in Immune Deficient Persons

      • David T. Purtilo

      Pages 3-17

   3. Relapsing, Recurrent, and Chronic Infectious Mononucleosis in the Normal Host

      • Stephen E. Straus

      Pages 18-33

   4. Immune Assessment of Patients with Chronic Active EBV Infection (CAEBV)

      • J. F. Jones, S. E. Straus, G. Tosato, R. A. Kibler, M. Hicks, D. Lucas et al.

      Pages 34-42

   5. Reversal of Common Variable Hypogammaglobulinemia-Associated Suppressor Cell Activity by Specific Carbohydrates

      • G. Tosato, S. E. Pike, R. M. Blaese

      Pages 43-52

   6. Unusual Primary Tumors of Brain and Lungs Associated with Epstein-Barr Virus (EBV)

      • J. Joncas, F. Ghibu, N. Lapointe, L. Begin, J. Michaud, P. Simard et al.

      Pages 53-62

   7. Lytic, Non-Transforming Epstein-Barr Virus (EBV) from Two Patients with Chronic Active EBV Infection

      • Carolina Alfieri, Félicia Ghibu, Jean Joncas

      Pages 63-72

   8. Brief Communication The Significance of Antibodies Against the Epstein-Barr Virus-Specific Membrane Antigen gp 250 in Acute and Latent EBV Infections

      • Wolfgang Jilg, Hans Wolf

      Pages 73-77

3. EBV-Associated Malignancies

   1. Front Matter

      Pages 79-79

      PDF

   2. The Epidemiology of Epstein-Barr Virus-Associated Malignancies

      • P. H. Levine

      Pages 81-89

   3. Genetic Aspects of EBV-Associated Malignancies

      • Malcolm J. Simons

      Pages 90-105

   4. Pathology of Epstein-Barr Virus (EBV)-Associated Disease (The Lymphatic System)

      • Gerhard R. F. Krueger

      Pages 106-130

   5. The “Family Study” Approach to Investigating the Role of Genetic Factors in Nasopharyngeal Carcinoma

      • Sherri J. Bale, Allen E. Bale, Paul H. Levine

      Pages 131-144

   6. An EBV-Associated Salivary Gland Cancer

      • Anne P. Lanier, Sarala Krishnamurthy, Susan E. Clift, Kathy T. Kline, Georg W. Bornkamm, Werner Henle et al.

      Pages 145-150

   7. Nasopharyngeal Carcinoma : Early Detection and IGA-Related Pre-NPC Condition.Achievements and Prospectives

      • Yi Zeng, Guy de The

      Pages 151-163

   8. Evaluation of Epstein-Barr Virus Serologic Analysis in North American Patients with Nasopharyngeal Carcinoma and in Comparison Groups

      • H. Bryan Neel III, Gary R. Pearson, William F. Taylor

      Pages 164-179

   9. Use of Epstein-Barr Virus Serology in the Diagnosis of Nasopharyngeal Carcinoma in Malaysia

      • M. Yadav, N. Malliha, A. W. Norhanom, U. Prasad

      Pages 180-192

   10. An Analysis of the Relationship Between Clinical Pathology and Serological Level of EB Virus VCA-IgA Antibody in Nasopharyngeal Carcinoma

       • Pei Sheng Huang, Yu Dong Chen, Yuin Yin Shen

       Pages 193-199

   11. Brief Communication Fossa of Rosenmuller: The Site for Initial Development of Carcinoma of the Nasopharynx

       • U. Prasad, J. Singh, R. Patmanathan

       Pages 200-206

It has been slightly more than two decades since the Epstein-Barr virus (EBV) was discovered by Prof. M.A. Epstein and his colleagues at the University of Bristol in their search for the causative agent of Burkitt's lymphoma. For several years EBV was a "virus in search of a disease." The first documentation that EBV was pathogenic for humans was in 1969 when Drs. Gertrude and Werner Henle identified it as the causative agent for infectious mononucleosis. Seroepidemiologic and biochemical studies subsequently linked EBV to Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), and more recently to the X-linked lymphoproliferative syndrome. With its widespread pattern of infection and a predilection for producing clinical signs and symptoms in only certain individuals, EBV has provided a model for many other candidate oncogenic viruses, including papilloma viruses, herpes simplex, and HTLV/LAV. In 1975, an international workshop was sponsored by the National Cancer Institute to address the problem of EBV production, thus facilitating basic research on the virus. This proved to be the last international meeting on EBV for almost a decade. In the past, progress in both clinical and basic research on EBV has been presented in two types of international meetings, the international herpesvirus workshops devoted primarily to basic research on both human and animal herpesviruses, and the international symposia on NPC, in which EBV-related studies were interspersed with clinical, epidemiologic and other etiologic aspects of this important human neoplasm.

• antibody
• antigen
• cancer
• cell
• documentation
• immunodeficiency
• immunology
• immunosuppression
• infection
• infectious
• lymphoma
• molecular biology
• neoplasm
• research
• virus

Policies and ethics